Logo
CustomersBlogPricingDemo
SIGN UP NOWBOOK A DEMO

What is the Fiscal Year for Lexeo Therapeutics?

Date: November 13, 2026


Lexeo Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.

Current Fiscal Year Overview

Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026

Quarterly Breakdown

Q1

Jan 1, 2026 – Mar 31, 2026

Q2

Apr 1, 2026 – Jun 30, 2026

Q3

Jul 1, 2026 – Sep 30, 2026

Q4

Oct 1, 2026 – Dec 31, 2026

Company Information

Headquarters

New York, New York

Industry

Biotechnology Research

Stock Symbol

LXEO

Website
https://lexeotx.com
Description

Based in New York City, Lexeo Therapeutics is a clinical-stage company dedicated to reshaping the path of genetic disease. Lexeo seeks to advance pioneering science to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. By taking aim at the underlying genetic cause of the devastating diseases we target, we seek to create substantial positive impact and reduce the overwhelming burdens placed on individuals receiving treatment, their caregivers, and healthcare systems. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and neurological diseases, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.


Use Salesmotion for Account Data and Insights

Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Lexeo Therapeutics and uncover key business information that drives smarter conversations.

Book a demo today to strengthen your sales strategy with powerful data and actionable insights.

BOOK A DEMO